GILD and Germany-based Tubulis collaborate to discover and develop an antibody-drug conjugate against a solid tumor target.

Gilead isn’t the only Big Pharma to take an interest in Tubulis’ ADC tech. BMS paid the company $23 million upfront in April ...

Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $92.49 which represents a decrease of $-1.53 or -1.63% from the prior close of $94.02. The stock opened at $93.81 and touched a low ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Tubulis today announced that they have entered into an exclusive option and license ...

The stock's fall snapped an eight-day winning streak.

Six years after first allying with Aelix Therapeutics to test the Spanish biotech’s HTI vaccine for HIV, Gilead Sciences has ...

Morrow County Food Pantry co-directors Brenda Harden and Teresa Shipman were delighted with the contributions from Mount ...

Justin Sullivan/Getty Images News Gilead Sciences (NASDAQ:GILD) shares logged in eight straight sessions of gains, as the ...

A judge Monday denied a bid by a former Gilead Sciences Inc. COO to transfer to Ventura County a sexual harassment lawsuit ...

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $75 ...

Sanofi just made its largest investment thus far in China. The company has committed just over $1 billion to build a new ...

Gilead (GILD) and Tubulis announced that they have entered into an exclusive option and license agreement to discover and develop an ...